Hancock Jaffe Laboratories, Inc. (HJLI)
|Net Income (ttm)||-7.08M|
|Trading Day||January 15|
|Day's Range||8.26 - 9.01|
|52-Week Range||6.75 - 18.81|
There are no news available yet.
Hancock Jaffe Laboratories, a medical device company, develops and sells tissue based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to... [Read more...]
Robert A. Berman
|Stock Exchange |
|Ticker Symbol |
In 2019, HJLI's revenue was $31,243, a decrease of -83.25% compared to the previous year's $186,552. Losses were -$7.63 million, -41.54% less than in 2018.
According to one analyst, the rating for HJLI stock is "Strong Buy" and the 12-month stock price forecast is 26.25.